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ABSTRAK
Kajian ini bertujuan untuk mengenal pasti faktor-faktor yang berkait dengan 
penyakit ginjal kronik tahap 3b di kalangan pesakit kencing manis yang dirawat 
di Pusat Perubatan Primer UKM, khususnya peranan dos ubatan yang menyekat 
angiotensin.  Kajian ini merupakan kajian kes-kawalan pilot yang tidak dipadankan 
dan dijalankan di sebuah pusat pengajaran perubatan primer. Data klinikal 25 kes 
pesakit dengan penyakit ginjal kronik tahap 3b (GFR 30-45ml/min/1.73m2) dalam 
tahun 2012 dipilih sebagai kes untuk kajian ini. Di samping itu, 103 pesakit diabetes 
yang mempunyai GFR lebih daripada 45ml/min/1.73m2 dalam tahun 2012 dipilih 
sebagai kawalan. Sampel dipilih secara rawak sistematik. Data pesakit diperolehi 
melalui rekod pesakit diabetes, sistem maklumat kesihatan komputer, dan fail 
perubatan pesakit. Analisis univariat menggunakan ujian chi square, t-test, Fisher’s 
exact test dan Mann-Whitney U-test. Regresi logistik digunakan untuk mengenal 
pasti faktor-faktor yang berkait dengan pembentukan penyakit ginjal kronik tahap 
3b. Kes dan kawalan berbeza dari segi umur, jangkamasa diabetes, penggunaan 
dan dos ubat penyekat angiotensin, tekanan darah sistolik dan GFR permulaan. 
Regresi logistic menunjukkan bahawa tekanan darah sistolik (Adjusted OR= 1.08, 
95% CI= 1.02-1.14, p=0.013) and GFR tahap asas (Adjusted OR= 0.90, 95% CI= 
0.85-0.95, p<0.001) berkait secara signifikan dengan pembentukan penyakit ginjal 
kronik tahap 3b di kalangan pesakit diabetes. Penggunaan dos ubat penyekat 
angiotensin yang maksimum memperlihatkan kesan perlindungan (Adjusted OR= 
0.14, 95% CI=0.85-0.95, p=0.025).  Kajian ini menyokong keperluan kawalan 
tekanan darah sistolik yang baik untuk melambatkan kemerosotan fungsi ginjal. 
Dos ubat penyekat angiotensin perlu dioptimumkan di kalangan pesakit-pesakit ini.
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Kata kunci: kajian kes-kawalan, kencing manis, perubatan primer, kelemahan fungsi 
ginjal, kronik
ABSTRACT
The present study aimed to determine the factors associated with CKD stage 3b 
among type 2 diabetics attending primary care follow-up, specifically the role 
of angiotensin blockade dosage. This was a pilot unmatched case-control study 
conducted in a teaching primary care centre. Clinical data of 25 cases of diabetic 
patients with CKD stage 3b (GFR 30-45ml/min/1.73m2) in 2012 were selected for 
this study, as well as 103 controls who were diabetic patients with GFR more than 
45ml/min/1.73m2 in 2012. Systematic random sampling was employed. Data was 
obtained from patients’ diabetic records, computerised clinical medical information 
system and medical case notes. Univariate analysis was done using Chi-square, 
t-test, Fisher’s exact test and Mann-Whitney U-test. Multiple logistic regression was 
used to determine the associated factors for development of CKD stage 3b. Cases 
and controls were different in terms of age, duration of diabetes, use and dosage 
of angiotensin blockade medications, systolic blood pressure and baseline GFR. 
Multiple logistic regression revealed that systolic blood pressure (Adjusted OR= 
1.08, 95% CI= 1.02-1.14, p=0.013) and baseline GFR (Adjusted OR= 0.90, 95% 
CI= 0.85-0.95, p<0.001) was significantly associated with the development of CKD 
stage 3b among diabetics. Maximizing the dose of angiotensin blockade had a 
protective effect (Adjusted OR= 0.14, 95% CI=0.85-0.95, p=0.025). The results of 
the present study supports the need for good control of systolic blood pressure 
among diabetic patients to reduce the risk of chronic kidney disease progression. 
Dose of angiotensin blockade medications should be optimised in these patients.
Keywords: case-control studies, diabetes mellitus, primary health care, renal 
insufficiency, chronic
In Malaysia, diabetic nephropathy 
contributed to more than half of new 
dialysis patients since 2003, and this 
number is progressively increasing 
(National Renal Registry 2011). In view 
of the increasing burden of chronic 
kidney disease, factors influencing the 
disease progress need to be identified 
to reduce end-stage renal failure.
 The average time for diabetics 
with CKD3 to progress to CKD stage 
4 is about three years (Meguro et al. 
INTRODUCTION
The prevalence of chronic kidney disease 
(CKD) and end-stage renal disease 
(ESRD) worldwide, ranges from 12.1% 
to 17.5% (Ingsathit et al. 2010; Centers 
for Disease Control and Prevention 
(CDC) 2007; Chen et al. 2009; Ong-
Ajyooth et al. 2009). Diabetes mellitus 
(DM) is the leading cause of CKD, 
accounting for approximately 30% to 
40% of CKD and up to 45% of ESRD 
(National Kidney Foundation 2004). 
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2009). Previous studies have shown 
that certain risk factors are associated 
with accelerated progression of 
CKD including older age, ethnicity, 
cigarette smoking, duration of diabetes, 
obesity, systemic hypertension, poor 
diabetes control and various levels of 
albuminuria (Meguro et al. 2009; Hsu 
et al. 2003; Keane et al. 2003; Orth & 
Hallan 2008).
 A retrospective cohort study 
conducted by Chia and Ching (2012) in 
the primary care setting focused on the 
role of hypertension in development 
of chronic kidney disease. This 
study found that older age, diabetes, 
hyperuricaemia and lower eGFR status 
was associated with the development 
of new onset chronic kidney disease. 
The aim of the present study was to 
identify the risk factors associated with 
CKD stage 3b and the effect of maximal 
dose of angiotensin blockade.
MATERIALS AND METHODS
SETTING
This was a pilot unmatched case-
control study conducted in a teaching 
primary care centre in Kuala Lumpur. 
Prior ethical approval was obtained 
from the Ethics Committee of UKMMC. 
A total of 25 cases of patients who 
had established CKD stage 3b (GFR 
between 30-45ml/min/1.73m2) and 
103 controls of patients with GFR of 
more than 45ml/min/1.73m2 in the year 
2012 were identified from the primary 
care clinic diabetic registry.  Systematic 
random sampling was used, where 
every fifth patient in the registry was 
selected. 
INCLUSION AND EXCLUSION 
CRITERIA
Diabetic patients who were on regular 
follow-up for at least five years at the 
primary care clinic were included. 
Patients with impaired fasting glucose 
or impaired glucose tolerance, those 
who developed CKD stage 4 and 5 on 
or before 2012, pregnant patients at 
any time during the 5-year of follow-
up and patients with other causes 
of chronic kidney disease such as 
autoimmune disease, obstructive 
uropathy, congenital kidney disease 
as well as drug-induced nephropathy, 
were excluded from this study.
DATA COLLECTION
Information on socio-demographic 
data, body mass index (BMI), systolic 
blood pressure (SBP) and the use of 
ACEIs or ARBs were collected from 
patients’ diabetic records. Dosages 
of angiotensin-blockade medications 
were further classified into submaximal 
and maximal dose. The glycosylated 
haemoglobin concentration (HbA1c) 
and serum creatinine levels were traced 
from the computerized clinical medical 
information system. Patients’ case files 
were reviewed for data the duration of 
DM. 
 The mean BMI over the five year 
period was calculated for analysis. 
The mean SBP and HbA1c of the 
first reading each year from 2008 
to 2012 were used for statistical 
analysis. Albuminuric status was 
defined as the latest investigated urine 
albumin within the five years, prior 
to recruitment and categorized into 
normoalbuminuric, microalbuminuric 
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and macroalbuminuric. The first serum 
creatinine levels for each year from 
2008 to 2012 were recorded.  
CLASSIFICATION OF CKD
When eGFR declines to less than 
60 mL/min/1.73m2, half of the renal 
function is lost and the prevalence 
of the complications of CKD, such as 
hypertension, anaemia, malnutrition, 
bone disease, neuropathy, and 
decreased quality of life, begins to rise 
(Cockcroft & Gault 1976; Swedko et al. 
2003; Levey et al. 2003). In this study, 
CKD stage 3b was selected as the 
outcome variable because it signifies 
the definite presence of pathological 
reduction of GFR (Levey et al. 2003). 
Studies have shown that there is a steep 
increase in risk of mortality in patients 
who have CKD stage 3b compared to 
with those having CKD stage 3a (Levey 
et al. 2011).
 The estimated glomerular filtration 
rate (eGFR) was used to determine 
renal function. In this study, eGFRwas 
calculated using Modification of Diet 
in Renal Disease (MDRD) equation and 
expressed in units of ml/min/1.73m2 
(Levey et al. 2003).
STATISTICAL ANALYSIS
All statistical analysis was performed 
using the IBM Statistical Package for 
Social Sciences (SPSS) version 21.0. 
Normally distributed data was described 
using mean and standard deviation, 
whereas skewed data was described 
using median and interquartile range. 
Univariate analysis was done using 
Chi-square, Fisher Exact test and 
Student t-test for parametric data, and 
Mann-Whitney U-test was used for 
non-parametric data. Multiple logistic 
regression was used to determine the 
association between the variables and 
the outcome.
RESULTS
A total of 865 diabetic patients were 
identified to have continued follow 
up care in the last five years at PPP-
UKMMC. Only twenty five of them 
had developed CKD stage 3b.  Since 
this number was small, the ratio of 
controls for each case was increased to 
4:1 in order to improve the power of the 
study.  
 Table 1 showed the socio-
demographic and clinical characteristics 
of the patients. They were significantly 
older (p=0.009) and had diabetes for 
a longer duration (p=0.002). They 
were more frequently prescribed with 
angiotensin blockade medications at 
the maximum dosage (64.0% p=0.001), 
had higher systolic blood pressure (155.2 
mmHg vs 140.8 mmHg, p<0.001) and 
lower baseline GFR (64.6 vs 92.4 ml/
min/1.73m2, p<0.001) compared to the 
controls.
 Multiple logistic regression using 
enter method was used to determine 
factors associated with the development 
of CKD stage 3b. The independent 
variables that were included into the 
model for multiple logistic regression 
were age, duration of diabetes, dosage 
of ACEI/ARB used, BMI, SBP, HbA1c, 
albuminuric status and baseline GFR. 
Use of ACEI/ARB could not be entered 
into the model for multiple logistic 
regression because all cases were on 
ACEI/ARB. Due to missing data, only 23 
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cases and 73 controls were retained for 
multivariate analysis.
 The logistic regression model was 
statistically significant (X2(8)= 57.7, 
p<0.001).  The model explained 68.5% 
(Nagelkerke R2) of the variance in 
development of CKD stage 3b among 
diabetics. We were able to correctly 
classify 89.6% of the cases, with a 
sensitivity of 72.7% and specificity of 
94.6%.  Three of the nine variables were 
found to be significantly associated 
with the development of CKD stage 
3b, namely systolic blood pressure, 
baseline GFR and use of maximal 
dosage of angiotensin blockade agents. 
The results were tabulated (Table 2).  
 Every increase of 1 mmHg in systolic 
blood pressure would increase the risk 
of developing CKD stage 3b by 8% 
(Adjusted OR=1.08, 95% CI= 1.02-1.14, 
p= 0.013).  Conversely, every reduction 
in baseline GFR would increase the risk 
of developing CKD stage 3b by 11% 
(adjusted OR 0.90, 95% CI= 0.85-0.95, 
p<0.001).  The use of maximum dosage 
Table 1: Socio-demographic and clinical characteristics of study population
Variable
Sample
p value
Case Control
Age (years) 69.69±8.56 64.49±9.70 0.009a
Gender
Male 9 (36.0%) 39 (37.9%)
0.863b
Female 16 (64.0%) 64 (62.1%)
Ethnicity
Malay 7(28.0%) 41(39.8%)
0.183bChinese 14(56.0%) 57(55.3%)
Indian 4(16.0%) 5(4.9%)
Duration of Diabetes (years) 11 (IQR6-20) 6 (IQR 5-9.25) 0.002c
Use of ACEI/ARB 
Use of ACEI/ARB 25 (100%) 86 (83.4%)
0.042d
No use of ACEI/ARB 0 (0%) 17 (16.5%)
Dosage of ACEI/ ARB
Maximal 16(64.0%) 21(24.4%)
<0.001b
Submaximal 9(36.0%) 65(75.6%)
Body Mass Index (kg/m2) 25.9 (IQR 24.8-29.9) 26.4 (IQR 23.4-29.3) 0.798c
Systolic Blood Pressure (mm Hg) 155.2±14.6 140.8±15.0 <0.001a
HbA1c level 7.0 (IQR 5.8-8.5) 6.7 (IQR 6.1-7.7) 0.417c
Albuminuric Status
Normoalbuminuria 9(36.0%) 52(50.5%)
0.067bMicro/macroalbuminuria 14 (56.0%) 34 (33.0%)
Not done 2 (8.0%) 17 (16.5%)
Baseline GFR (ml/min/1.73m2) 64.56±18.64 92.40±24.57 <0.001a
a = Student t-test; b = Chi-square test; c= Mann-Whitney U test; d= Fisher Exact test
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of angiotensin blockade reduced the 
risk of developing CKD stage 3b by 7.2 
times (adjusted OR=0.14, 95% CI=0.03-
0.78, p= 0.025).
DISCUSSION
Systolic blood pressure is an established 
risk factor for the development of 
chronic kidney disease (Haroun et al. 
2003; Bakris et al. 2003; Ingsathit et al. 
2010; Hooi et al. 2013). The finding of 
this study was consistent with earlier 
studies, supporting the importance of 
blood pressure control in preventing 
renal complications among diabetics. 
Unfortunately, only a quarter of patients 
with diabetes in the primary care 
setting manage to achieve targets for 
blood pressure control (Cheong et al. 
2013). This places Malaysian diabetics 
at higher risk of developing chronic 
kidney disease. 
 Hypertension and chronic 
kidney disease form a vicious cycle.
Hypertension is a proven predictor 
of development of renal impairment, 
whereas presence of renal impairment 
increases blood pressure and affects 
blood pressure control (Bakris et al. 
2003; Haroun et al. 2003; Sarafidis 
et al. 2008). Despite the variability of 
GFR decline, progression to end stage 
renal disease is increased whenever the 
baseline GFR is lower (Li et al. 2012). 
The findings of the present study were 
similar to an earlier cohort study which 
looked into trajectories of GFR among 
patients with CKD (Li et al. 2012).
 Many landmark trials demonstrated 
the benefits of angiotensin blockade 
medications in delaying the progression 
of diabetic nephropathy (Heart 
Outcomes Prevention Evaluation 
Study Investigators 2000; Ravid et 
al. 1998; The Diabetes Control and 
Complications (DCCT) Research Group 
1995). Our findings confirmed that 
by optimising the dose of angiotensin 
blockade among hypertensive 
diabetics, the risk of developing severe 
chronic kidney disease was reduced 
Table 2: Multiple logistic regression for predicting factors associated with CKD stage 3b
Variables Beta S.E Wald p value Adjusted Odd Ratio 95% CI
Age 0.061 0.047 1.655 0.198 1.06 0.97-1.17
Duration of DM 0.018 0.043 0.177 0.674 1.02 0.94-1.11
Body mass index (BMI) 0.017 0.097 0.032 0.858 1.02 0.84-1.23
Systolic blood pressure 0.072 0.029 6.226 0.013 1.08 1.02-1.14
HbA1c 0.353 0.297 1.405 0.236 1.42 0.79-2.55
Baseline GFR -0.104 0.029 12.662 <0.001 0.90 0.85-0.95
Dose of ACEI/ARB
Submaximal dose 1
Maximal dose -1.973 0.881 5.015 0.025 0.14 0.03-0.78
Albuminuric Status
Normoalbuminuria 1
Micro- and macroalbuminuria -0.073 0.922 0.006 0.937 0.94 0.15-5.66
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by seven times. Although the use of 
angiotensin blockade agents among 
diabetics with hypertension have 
increased in the recent years, there 
is no published data regarding the 
dosage of such agents used in the 
local population (Chan 2005; Chew et 
al. 2010). There is a need to increase 
awareness to family physicians that the 
renoprotective effects of ACE inhibitors 
and angiotensin receptor blockers are 
best when maximum recommended 
dosage is used. However, this practice 
needs to be done with monitoring to 
avoid problems such as angiotensin-
blockade related renal failure and 
hyperkalaemia.  
 A cross-sectional study in Malaysia 
showed that prescription of ACE 
inhibitors and ARBs were still very 
low among diabetic patients in 2003 
(Chan 2005). Another study showed 
that 68.1% of diabetics were on ACE 
inhibitors, whereas 7.6% of diabetics 
were on ARBs (Cheong et al. 2013). This 
could be attributed to higher adoption 
of local clinical practice guideline 
by physicians. The improvement in 
prescribing patterns for such agents 
is thought to reduce the incidence of 
diabetic nephropathy and new-onset 
chronic kidney disease.  
 Currently, there is no published data 
regarding the proportion of diabetic 
patients who are being prescribed 
the maximum dose of ACEI or ARBs. 
Clinical audits should be done in order 
to study the prescribing patterns of such 
agents in order to maximize its benefits 
on reducing the risk of developing 
severe chronic kidney disease.
 This study was carried out in a primary 
care setting, where development of 
chronic kidney disease is usually first 
diagnosed. The clinical profiles of 
patients in a primary care clinic are 
different from those found in secondary 
or tertiary care, which caters to patients 
with more complicated problems.  CKD 
stage 3b is usually detected in primary 
care clinics.  Intervention at this stage 
could delay the progression to more 
severe stages of CKD.
 Limitations of this study include the 
small sample size due to lack of eligible 
cases. Therefore, this study may be 
underpowered to detect significant 
associations for other factors such as age, 
duration of diabetes, HbA1c and BMI. 
However, clinicians should continue 
to address modifiable risk factors such 
as glycemic control and body weight 
among diabetic patients who are at 
risk of developing CKD.  Secondly, the 
baseline characteristics of cases and 
controls were different in many aspects. 
Therefore, multiple logistic regression 
was used in order to control for the 
effect of confounding factors.  All cases 
were on ACE/ARB in this study. The 
researchers were unable to analyse 
whether use or non-use of ACEI/ARB 
affected the development of CKD stage 
3b. Being a retrospective study, there 
were some problems of missing data. 
Hence, a definite causal relationship 
between the associated factors and the 
development of CKD stage 3b could 
not be demostrated.  Patient adherence 
to ACEI/ARB, interaction with other 
medications and possible concomitant 
use of nephrotoxic drugs were other 
possible confounding factors which 
could not be addressed in this study.  
 It is recommended that predictors 
of CKD in the primary care setting 
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are studied further by conducting a 
multi-centered, cohort study in order 
to further establish the relationship 
of maximal dose of ACEI/ARB with 
delaying onset of CKD stage 3b among 
diabetics.  
CONCLUSION
Systolic blood pressure and lower 
baseline GFR are significantly 
associated with the development of 
CKD stage 3b in the primary care 
setting. The use of maximum dosage 
of angiotensin blockade agents was 
found to have protective effect towards 
the development of CKD stage 3b. 
Primary care doctors should aim for 
better control of blood pressure among 
and to optimise the dose of angiotensin 
blockade agents among diabetic 
patients. However, use of maximum 
dose of such agents should be done 
with appropriate monitoring to prevent 
drug-related adverse events.  
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